Deals
After being bought by Bain for $3.3 billion, Tanabe has reached a deal to sell its manufacturing unit and 17 products.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Retrophin, Inc. announced that Company management will present at the following upcoming investor conferences in June
Probiodrug AG, announces that its shareholders approved all resolutions proposed by the Company’s Management and Supervisory Board at the Company’s Annual General Meeting which took place on Wednesday, May 29, 2019
Upon approval by the shareholders, ASIT biotech expects to raise between €9M and €12M of convertible notes to finance its focused development
The company’s board of directors hasn’t made a final decision to proceed with the listing.
Domain Therapeutics announces that it has secured a €3.5M investment from existing shareholder Seventure Partners, to accelerate its next growth phase.
MorphoSys AG will present at the following conferences
Stoke focuses on treating genetic diseases by upregulating protein expression. Its lead compound, STK-001, is focused on Dravet syndrome, a rare form of epilepsy that starts in infancy.
ADL Bionatur Solutions recently reported Q119 results, showing positive €0.11m EBITDA, and over 134% year-on-year revenue growth to €10m, driven by 180% growth in contract manufacturing.
Polarean Imaging plc, the medical-imaging technology company, with a proprietary drug-device combination product for the magnetic resonance imaging market, announces it will be hosting a Capital Markets Day for all investors on Wednesday 12 June 2019.
Auris Medical Holding Ltd. provided a business update, including a review of recent clinical, regulatory and operational highlights and progress.